DE3729209C2 - - Google Patents

Info

Publication number
DE3729209C2
DE3729209C2 DE3729209A DE3729209A DE3729209C2 DE 3729209 C2 DE3729209 C2 DE 3729209C2 DE 3729209 A DE3729209 A DE 3729209A DE 3729209 A DE3729209 A DE 3729209A DE 3729209 C2 DE3729209 C2 DE 3729209C2
Authority
DE
Germany
Prior art keywords
bezafibrate
insulin
glucose
treatment
triglyceride
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired
Application number
DE3729209A
Other languages
German (de)
English (en)
Other versions
DE3729209A1 (de
Inventor
Walter Dipl.-Chem. Dr.Rer.Nat. 6800 Mannheim De Beck
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Roche Diagnostics GmbH
Original Assignee
Boehringer Mannheim GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Boehringer Mannheim GmbH filed Critical Boehringer Mannheim GmbH
Priority to DE19873729209 priority Critical patent/DE3729209A1/de
Priority to IE252988A priority patent/IE62189B1/en
Priority to DK472688A priority patent/DK472688A/da
Priority to ES88113831T priority patent/ES2059457T3/es
Priority to DE88113831T priority patent/DE3884895D1/de
Priority to EP88113831A priority patent/EP0305890B1/de
Priority to HU884456A priority patent/HU200687B/hu
Priority to AT88113831T priority patent/ATE95694T1/de
Priority to IL87566A priority patent/IL87566A0/xx
Priority to PH37464A priority patent/PH24568A/en
Priority to AU21586/88A priority patent/AU610228B2/en
Priority to PT88383A priority patent/PT88383B/pt
Priority to CA000576196A priority patent/CA1323575C/en
Priority to ZA886459A priority patent/ZA886459B/xx
Priority to JP63216469A priority patent/JP2647918B2/ja
Priority to KR1019880011350A priority patent/KR890004690A/ko
Publication of DE3729209A1 publication Critical patent/DE3729209A1/de
Application granted granted Critical
Publication of DE3729209C2 publication Critical patent/DE3729209C2/de
Priority to US07/993,525 priority patent/US5304575A/en
Granted legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics

Landscapes

  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Diabetes (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Obesity (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
DE19873729209 1987-09-01 1987-09-01 Verwendung von bezafibrat zur behandlung von diabetes Granted DE3729209A1 (de)

Priority Applications (17)

Application Number Priority Date Filing Date Title
DE19873729209 DE3729209A1 (de) 1987-09-01 1987-09-01 Verwendung von bezafibrat zur behandlung von diabetes
IE252988A IE62189B1 (en) 1987-09-01 1988-08-18 Use of bezafibrate for treating diabetes
DK472688A DK472688A (da) 1987-09-01 1988-08-24 Anvendelse af bezafibrat til behandling af diabetes
IL87566A IL87566A0 (en) 1987-09-01 1988-08-25 Medical composition for the treatment of diabetes comprising a benzamide derivative
DE88113831T DE3884895D1 (de) 1987-09-01 1988-08-25 Verwendung von Bezafibrat zur Behandlung von Diabetes.
EP88113831A EP0305890B1 (de) 1987-09-01 1988-08-25 Verwendung von Bezafibrat zur Behandlung von Diabetes
HU884456A HU200687B (en) 1987-09-01 1988-08-25 Process for producing pharmaceutical composition comprising bezafibrate as active ingredient and suitable for treating normolipidaemic diabetes
AT88113831T ATE95694T1 (de) 1987-09-01 1988-08-25 Verwendung von bezafibrat zur behandlung von diabetes.
ES88113831T ES2059457T3 (es) 1987-09-01 1988-08-25 Utilizacion de bezafibrato para el tratamiento de la diabetes.
AU21586/88A AU610228B2 (en) 1987-09-01 1988-08-26 Use of bezafibrate for treating diabetes
PH37464A PH24568A (en) 1987-09-01 1988-08-26 Use of bezafibrate for treating diabetes
PT88383A PT88383B (pt) 1987-09-01 1988-08-31 Processo para a preparacao de composicoes farmaceuticas contendo acido 2-<4-{2-(4-clorobenzamido)-etil}-fenoxi>-2-metil-propoionico apropriadas para o tratamento de diabetes
CA000576196A CA1323575C (en) 1987-09-01 1988-08-31 Use of bezafibrate for treating diabetes
ZA886459A ZA886459B (en) 1987-09-01 1988-08-31 Use of bezafibrate for treating diabetes
JP63216469A JP2647918B2 (ja) 1987-09-01 1988-09-01 正常脂血症性真性糖尿病▲ｉｉ▼型の予防剤
KR1019880011350A KR890004690A (ko) 1987-09-01 1988-09-01 당뇨병의 치료를 위한 베자피브레이드의 용도
US07/993,525 US5304575A (en) 1987-09-01 1992-12-17 Use of bezafibrate for treating diabetes

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE19873729209 DE3729209A1 (de) 1987-09-01 1987-09-01 Verwendung von bezafibrat zur behandlung von diabetes

Publications (2)

Publication Number Publication Date
DE3729209A1 DE3729209A1 (de) 1989-03-09
DE3729209C2 true DE3729209C2 (OSRAM) 1989-08-03

Family

ID=6334986

Family Applications (2)

Application Number Title Priority Date Filing Date
DE19873729209 Granted DE3729209A1 (de) 1987-09-01 1987-09-01 Verwendung von bezafibrat zur behandlung von diabetes
DE88113831T Expired - Fee Related DE3884895D1 (de) 1987-09-01 1988-08-25 Verwendung von Bezafibrat zur Behandlung von Diabetes.

Family Applications After (1)

Application Number Title Priority Date Filing Date
DE88113831T Expired - Fee Related DE3884895D1 (de) 1987-09-01 1988-08-25 Verwendung von Bezafibrat zur Behandlung von Diabetes.

Country Status (16)

Country Link
US (1) US5304575A (OSRAM)
EP (1) EP0305890B1 (OSRAM)
JP (1) JP2647918B2 (OSRAM)
KR (1) KR890004690A (OSRAM)
AT (1) ATE95694T1 (OSRAM)
AU (1) AU610228B2 (OSRAM)
CA (1) CA1323575C (OSRAM)
DE (2) DE3729209A1 (OSRAM)
DK (1) DK472688A (OSRAM)
ES (1) ES2059457T3 (OSRAM)
HU (1) HU200687B (OSRAM)
IE (1) IE62189B1 (OSRAM)
IL (1) IL87566A0 (OSRAM)
PH (1) PH24568A (OSRAM)
PT (1) PT88383B (OSRAM)
ZA (1) ZA886459B (OSRAM)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7655699B1 (en) 1992-04-22 2010-02-02 Eisai Inc. Compounds having selective activity for retinoid X receptors, and means for modulation of processes mediated by retinoid X receptors
US7115728B1 (en) 1995-01-30 2006-10-03 Ligand Pharmaceutical Incorporated Human peroxisome proliferator activated receptor γ
TWI238064B (en) * 1995-06-20 2005-08-21 Takeda Chemical Industries Ltd A pharmaceutical composition for prophylaxis and treatment of diabetes
WO1998005331A2 (en) * 1996-08-02 1998-02-12 Ligand Pharmaceuticals Incorporated Prevention or treatment of type 2 diabetes or cardiovascular disease with ppar modulators
AU8588798A (en) * 1997-07-25 1999-02-16 Institut Pasteur Human peroxisome proliferator activated receptor gamma (ppargamma) gene re gulatory sequences and uses therefor
FR2774591B1 (fr) * 1998-02-12 2000-05-05 Lipha Composition pharmaceutique comprenant l'association metformine et fibrate et son utilisation pour la preparation de medicaments destines a reduire l'hyperglycemie
AU2001236457A1 (en) 2000-01-13 2001-07-24 Emisphere Technologies, Inc. Compounds and compositions for delivering active agents
JP4417113B2 (ja) 2002-02-20 2010-02-17 エミスフェアー・テクノロジーズ・インク Ｇｌｐ−１分子の投与方法
US7264813B2 (en) * 2003-09-24 2007-09-04 Nikken Sohonsha Corporation Therapeutic uses of Dunaliella powder
US20060286129A1 (en) * 2003-12-19 2006-12-21 Emisphere Technologies, Inc. Oral GLP-1 formulations
JP4901218B2 (ja) * 2004-02-09 2012-03-21 あすか製薬株式会社 併用医薬
FR2898894B1 (fr) * 2006-03-24 2008-06-06 Genfit Sa Composes derives de n-(phenethyl)benzamide substitues, preparation et utilisations
US10098860B2 (en) * 2016-07-20 2018-10-16 Cipla Limited Bezafibrate for the treatment of cancer

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2149070C3 (de) * 1971-10-01 1978-03-23 Boehringer Mannheim Gmbh, 6800 Mannheim Phenoxyalkylcarbonsäurederivate und deren Salze, Verfahren zu deren Herstellung und Arzneimittel
JPS56145261A (en) * 1980-04-10 1981-11-11 Kaken Pharmaceut Co Ltd Novel oxyacetic acid derivative, its preparation, and lowering agent of lipid in blood comprising it as active ingredient

Also Published As

Publication number Publication date
ES2059457T3 (es) 1994-11-16
KR890004690A (ko) 1989-05-09
EP0305890B1 (de) 1993-10-13
IE62189B1 (en) 1994-12-28
IE882529L (en) 1989-03-01
PT88383B (pt) 1992-10-30
CA1323575C (en) 1993-10-26
DK472688D0 (da) 1988-08-24
DE3884895D1 (de) 1993-11-18
EP0305890A3 (en) 1990-08-22
JP2647918B2 (ja) 1997-08-27
JPS6471813A (en) 1989-03-16
EP0305890A2 (de) 1989-03-08
AU610228B2 (en) 1991-05-16
IL87566A0 (en) 1989-01-31
PH24568A (en) 1990-08-03
ZA886459B (en) 1989-05-30
DK472688A (da) 1989-03-02
HU200687B (en) 1990-08-28
ATE95694T1 (de) 1993-10-15
AU2158688A (en) 1989-05-25
US5304575A (en) 1994-04-19
HUT47427A (en) 1989-03-28
PT88383A (pt) 1989-07-31
DE3729209A1 (de) 1989-03-09

Similar Documents

Publication Publication Date Title
DE3729209C2 (OSRAM)
DE69800806T2 (de) Neue dosierung für diabetes type 2
DE69109376T2 (de) Hemmung von Muskelschwund und Proteinabbau von Muskeln bei Säugetieren durch Tetrazyklines.
DE69529249T2 (de) Puderpräparat zur Heilung verletzter Haut
DE69829763T2 (de) Verwendung von tetrahydolipstatin in der behandlung von diabetes typ ii
DE3314150C2 (de) Zahnzement, enthaltend Tanninderivate
DE2241740A1 (de) Pharmazeutische packungen
DE4214953C2 (de) Arzneimittel zur Erhöhung des Testosteronspiegels
DE69110779T2 (de) Schilddrüsenhormone zur kardialen behandlung.
DE3880587T2 (de) Verwendung von bestimmten calcium-citrate-malaten zur herstellung einer pharmazeutischen zubereitung fuer die behandlung von osteoporose.
EP0398165B1 (de) Kombinationspräparate enthaltend Rifampicin und Thioacetazon sowie gegebenenfalls Isonicotinsäurehydrazid oder Ethambutol als aktive Wirkstoffe
DE3530256A1 (de) Verwendung von probucol bei der behandlung von herzarrhythmie
CH649918A5 (de) Verwendung von n-amidino-2-phenylacetamiden als wirkstoff zur herstellung von pharmazeutischen zubereitungen gegen schizophrenie.
Bojanovsky et al. Der Einfluß der antidepressiven Therapie auf das gestörte Zeiterleben depressiver Patienten
DE69019956T2 (de) Pharmazeutische zusammensetzungen zur behandlung von hauterkrankungen, insbesondere pyogener und atopischer dermatitis und verfahren zu deren herstellung.
DE69027577T2 (de) Verwendung von Benzothiazepinen zur Herstellung von Arzneimitteln zur Behandlung von epileptischen Anfällen
Groh et al. ORALE DAUERTHERAPIE MIT CLONAZEPAM (Ro 5‐4023) BEI EPILEPSIEN DES KINDES‐UND JUGENDALTERS
DE3722774C2 (OSRAM)
DE2630326C2 (de) Präparat zur Behandlung der Osteoporose und seine Herstellung
DE4240329C2 (de) Arzneimittel zur äußerlichen Behandlung von Gewebedefekten
Habeck Liquoreiweißbild und Pneumencephalogramm
DE2244909A1 (de) Arzneipraeparate zur behandlung von diabetes mellitus
Cysarz et al. Wirkung von Cardiodoron® auf die kardiorespiratorische Koordination–ein Literaturüberblick
Brodowski et al. Dentinuberempfindlichkeit-eine Ubersicht
DE3802895A1 (de) Kombinationspraeparat zur behandlung von nervenzell- und nervenfasererkrankungen und verletzungen

Legal Events

Date Code Title Description
OP8 Request for examination as to paragraph 44 patent law
D2 Grant after examination
8364 No opposition during term of opposition
8339 Ceased/non-payment of the annual fee